Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept

J-P Ortonne, A Taïeb, A D Ormerod, D Robertson, J Foehl, R Pedersen, C Molta, B Freundlich

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

BACKGROUND: Patients with psoriasis experience remission and gradual reappearance of erythematous and scaly plaques and require individualized treatment over time. A goal of psoriasis treatment is to provide optimal efficacy with a flexible therapeutic regimen that may include treatment pauses. OBJECTIVES: To determine whether patients receiving initial treatment with etanercept who then pause therapy would subsequently recapture response during re-treatment. PATIENTS AND METHODS: A post-hoc analysis of 226 patients with moderate-to-severe psoriasis from a large multicentre trial was performed. Patients had received etanercept 50 mg twice weekly subcutaneously until a target clinical response had been achieved, then had paused treatment and eventually relapsed. They were then re-treated with etanercept 25 mg twice weekly. The number of patients recapturing a Physician Global Assessment (PGA) of psoriasis rating of <or = 2 (clear, almost clear or mild) on first re-treatment was assessed. Patient satisfaction during the initial treatment and first re-treatment period was also determined. RESULTS: A total of 187 (83%) patients recaptured the target clinical response of a PGA of <or = 2 after re-treatment. The majority of patients [219 of 226 (97%)] reported satisfaction with etanercept re-treatment. No new safety concerns emerged during re-treatment. CONCLUSIONS: In this post-hoc analysis, patients with psoriasis who were re-treated with etanercept 25 mg twice weekly effectively recaptured clinical responses that patients found satisfactory. A flexible treatment option is available to dermatologists and patients for individualized care.
Original languageEnglish
Pages (from-to)1190-1195
Number of pages6
JournalBritish Journal of Dermatology
Volume161
Issue number5
Early online date21 May 2009
DOIs
Publication statusPublished - Nov 2009

Fingerprint

Psoriasis
Therapeutics
Etanercept
Physicians
Patient Satisfaction
Multicenter Studies
Patient Care

Keywords

  • adult
  • female
  • humans
  • immunoglobulin G
  • immunosuppressive agents
  • male
  • middle aged
  • patient satisfaction
  • psoriasis
  • receptors, tumor necrosis factor
  • recurrence
  • retreatment
  • efficacy
  • etanercept
  • re-treatment

Cite this

Ortonne, J-P., Taïeb, A., Ormerod, A. D., Robertson, D., Foehl, J., Pedersen, R., ... Freundlich, B. (2009). Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. British Journal of Dermatology, 161(5), 1190-1195. https://doi.org/10.1111/j.1365-2133.2009.09238.x

Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. / Ortonne, J-P; Taïeb, A; Ormerod, A D; Robertson, D; Foehl, J; Pedersen, R; Molta, C; Freundlich, B.

In: British Journal of Dermatology, Vol. 161, No. 5, 11.2009, p. 1190-1195.

Research output: Contribution to journalArticle

Ortonne, J-P, Taïeb, A, Ormerod, AD, Robertson, D, Foehl, J, Pedersen, R, Molta, C & Freundlich, B 2009, 'Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept', British Journal of Dermatology, vol. 161, no. 5, pp. 1190-1195. https://doi.org/10.1111/j.1365-2133.2009.09238.x
Ortonne, J-P ; Taïeb, A ; Ormerod, A D ; Robertson, D ; Foehl, J ; Pedersen, R ; Molta, C ; Freundlich, B. / Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. In: British Journal of Dermatology. 2009 ; Vol. 161, No. 5. pp. 1190-1195.
@article{18deb6609c3542c0826c07ce66586846,
title = "Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept",
abstract = "BACKGROUND: Patients with psoriasis experience remission and gradual reappearance of erythematous and scaly plaques and require individualized treatment over time. A goal of psoriasis treatment is to provide optimal efficacy with a flexible therapeutic regimen that may include treatment pauses. OBJECTIVES: To determine whether patients receiving initial treatment with etanercept who then pause therapy would subsequently recapture response during re-treatment. PATIENTS AND METHODS: A post-hoc analysis of 226 patients with moderate-to-severe psoriasis from a large multicentre trial was performed. Patients had received etanercept 50 mg twice weekly subcutaneously until a target clinical response had been achieved, then had paused treatment and eventually relapsed. They were then re-treated with etanercept 25 mg twice weekly. The number of patients recapturing a Physician Global Assessment (PGA) of psoriasis rating of <or = 2 (clear, almost clear or mild) on first re-treatment was assessed. Patient satisfaction during the initial treatment and first re-treatment period was also determined. RESULTS: A total of 187 (83{\%}) patients recaptured the target clinical response of a PGA of <or = 2 after re-treatment. The majority of patients [219 of 226 (97{\%})] reported satisfaction with etanercept re-treatment. No new safety concerns emerged during re-treatment. CONCLUSIONS: In this post-hoc analysis, patients with psoriasis who were re-treated with etanercept 25 mg twice weekly effectively recaptured clinical responses that patients found satisfactory. A flexible treatment option is available to dermatologists and patients for individualized care.",
keywords = "adult, female, humans, immunoglobulin G, immunosuppressive agents, male, middle aged, patient satisfaction, psoriasis, receptors, tumor necrosis factor, recurrence, retreatment, efficacy, etanercept, re-treatment",
author = "J-P Ortonne and A Ta{\"i}eb and Ormerod, {A D} and D Robertson and J Foehl and R Pedersen and C Molta and B Freundlich",
year = "2009",
month = "11",
doi = "10.1111/j.1365-2133.2009.09238.x",
language = "English",
volume = "161",
pages = "1190--1195",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley",
number = "5",

}

TY - JOUR

T1 - Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept

AU - Ortonne, J-P

AU - Taïeb, A

AU - Ormerod, A D

AU - Robertson, D

AU - Foehl, J

AU - Pedersen, R

AU - Molta, C

AU - Freundlich, B

PY - 2009/11

Y1 - 2009/11

N2 - BACKGROUND: Patients with psoriasis experience remission and gradual reappearance of erythematous and scaly plaques and require individualized treatment over time. A goal of psoriasis treatment is to provide optimal efficacy with a flexible therapeutic regimen that may include treatment pauses. OBJECTIVES: To determine whether patients receiving initial treatment with etanercept who then pause therapy would subsequently recapture response during re-treatment. PATIENTS AND METHODS: A post-hoc analysis of 226 patients with moderate-to-severe psoriasis from a large multicentre trial was performed. Patients had received etanercept 50 mg twice weekly subcutaneously until a target clinical response had been achieved, then had paused treatment and eventually relapsed. They were then re-treated with etanercept 25 mg twice weekly. The number of patients recapturing a Physician Global Assessment (PGA) of psoriasis rating of <or = 2 (clear, almost clear or mild) on first re-treatment was assessed. Patient satisfaction during the initial treatment and first re-treatment period was also determined. RESULTS: A total of 187 (83%) patients recaptured the target clinical response of a PGA of <or = 2 after re-treatment. The majority of patients [219 of 226 (97%)] reported satisfaction with etanercept re-treatment. No new safety concerns emerged during re-treatment. CONCLUSIONS: In this post-hoc analysis, patients with psoriasis who were re-treated with etanercept 25 mg twice weekly effectively recaptured clinical responses that patients found satisfactory. A flexible treatment option is available to dermatologists and patients for individualized care.

AB - BACKGROUND: Patients with psoriasis experience remission and gradual reappearance of erythematous and scaly plaques and require individualized treatment over time. A goal of psoriasis treatment is to provide optimal efficacy with a flexible therapeutic regimen that may include treatment pauses. OBJECTIVES: To determine whether patients receiving initial treatment with etanercept who then pause therapy would subsequently recapture response during re-treatment. PATIENTS AND METHODS: A post-hoc analysis of 226 patients with moderate-to-severe psoriasis from a large multicentre trial was performed. Patients had received etanercept 50 mg twice weekly subcutaneously until a target clinical response had been achieved, then had paused treatment and eventually relapsed. They were then re-treated with etanercept 25 mg twice weekly. The number of patients recapturing a Physician Global Assessment (PGA) of psoriasis rating of <or = 2 (clear, almost clear or mild) on first re-treatment was assessed. Patient satisfaction during the initial treatment and first re-treatment period was also determined. RESULTS: A total of 187 (83%) patients recaptured the target clinical response of a PGA of <or = 2 after re-treatment. The majority of patients [219 of 226 (97%)] reported satisfaction with etanercept re-treatment. No new safety concerns emerged during re-treatment. CONCLUSIONS: In this post-hoc analysis, patients with psoriasis who were re-treated with etanercept 25 mg twice weekly effectively recaptured clinical responses that patients found satisfactory. A flexible treatment option is available to dermatologists and patients for individualized care.

KW - adult

KW - female

KW - humans

KW - immunoglobulin G

KW - immunosuppressive agents

KW - male

KW - middle aged

KW - patient satisfaction

KW - psoriasis

KW - receptors, tumor necrosis factor

KW - recurrence

KW - retreatment

KW - efficacy

KW - etanercept

KW - re-treatment

U2 - 10.1111/j.1365-2133.2009.09238.x

DO - 10.1111/j.1365-2133.2009.09238.x

M3 - Article

VL - 161

SP - 1190

EP - 1195

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 5

ER -